Funding sources for public health research in Italy
Keywords:
Funding, public health, research, communicable diseases, non-communicable diseases, vaccinesAbstract
Background. Funding sources play a critical role in shaping the landscape of scientific research, including the one in public health, as they often determine not only the feasibility of specific projects but also its broader directions.
Study design. We aimed at assessing current funding sources for public health research in Italy and related implications.
Methods. We conducted a systematic PubMed search from January 2023 to June 2024, focusing on publications by 208 Italian tenured professors in hygiene and public health. We included only original articles they authored as first or last authors, excluding editorials, comments, and letters. We categorized funding sources into public internal, public external, private external, and unmentioned.
Results. We retrieved 760 non-duplicate eligible publications. Research topics focused almost equally on communicable (48.2%) and non-communicable (51.8%) diseases. Public external funding were the most common overall (33.7%), followed by private external (14.3%) and public internal (7.5%). Notably, 58.7% of studies did not report any funding sources. Private external, regional and EU sources predominantly funded communicable disease research, while non-communicable disease research received more support from public external sources, especially governmental.
Conclusions. In a European country such as Italy the funding landscape in public health research appears to be complex, due to the wide range of topics and intertwined roles of funding actors. Public funding are more frequent than private funding also independently of research topics, though most research activities did not require specific financial support, implying that public health research frequently has limited financial needs. This likely enables more flexibility and independence to investigators in public health, with major implications in terms of feasibility and absence of conflicts of interest.
References
1. El-Jardali F, Fadlallah R, Bou Karroum L, Akl EA. Evidence synthesis to policy: development and implementation of an impact-oriented approach from the Eastern Mediterranean Region. Health Res Policy Syst. 2023 Jun 1;21(1):40. doi: 10.1186/s12961-023-00989-5. PMID: 37264415; PMCID: PMC10234246.
2. Jit M, Cook AR. Informing public health policies with models for disease burden, impact evaluation, and economic evaluation. Annu Rev Public Health. 2024 May;45(1):133-150. doi: 10.1146/annurev-publhealth-060222-025149. Epub 2024 Apr 3. PMID: 37871140.
3. Equator Network. Enhancing the QUAlity and Transparency Of health Research; 2024. Available from: https://www.equator-network.org/. [Last accessed: 2024 October 23].
4. Huang M-H, Huang M-J. An analysis of global research funding from subject field and funding agencies perspectives in the G9 countries. Scientometrics. 2018;115(2):833-847. doi: 10.1007/s11192-018-2677-y.
5. Ministry of University and Research. Italian strategy for basic research [Strategia italiana per la ricerca fondamentale]; 2022. Available from: https://www.mur.gov.it/it/news/martedi-19072022/strategia-italiana-la-ricerca-fondamentale-ecco-la-proposta-oltre-il-pnrr. [Last accessed: 2024 October 23].
6. European Union. Researchers across Europe receive €544m in grants from European Research Council; 2023. Available from: https://erc.europa.eu/news-events/news/erc-2022-advanced-grants-results. [Last accessed: 2024 October 23].
7. European Union. Horizon Europe Implementation: Key Figures 2021 – 2023. European Union; May 2024. doi: 10.2777/646835.
8. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31;326(7400):1167-1170. doi: 10.1136/bmj.326.7400.1167. PMID: 12775614; PMCID: PMC156458.
9. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017 Feb 16;2(2):MR000033. doi: 10.1002/14651858.MR000033.pub3. PMID: 28207928; PMCID: PMC8132492.
10. Tortorice D, Rappuoli R, Bloom DE. The economic case for scaling up health research and development: lessons from the COVID-19 pandemic. Proc Natl Acad Sci U S A. 2024 Jun 25;121(26):e2321978121. doi: 10.1073/pnas.2321978121. Epub 2024 Jun 17. PMID:
38885387; PMCID: PMC11214072.
11. Vinceti SR, Filippini T. Revising the legislation of Ethics Committees to ease biomedical research in humans across the world: lessons from the COVID-19 emergency. Acta Biomed. 2022 May 11;93(2):e2021579. doi: 10.23750/abm.v93i2.12582. PMID: 35546005; PMCID: PMC9171886.
12. Aagaard K, Mongeon P, Ramos-Vielba I, Thomas DA. Getting to the bottom of research funding: acknowledging the complexity of funding dynamics. PLoS One. 2021;16(5):e0251488. doi: 10.1371/journal.pone.0251488. PMID: 33979400; PMCID: PMC8115833.
13. Italian National Institute of Statistics (ISTAT). Research and development report in Italy - 2020-2022 [Report ricerca e sviluppo in Italia - 2020-2022]: Italian National Institute of Statistics; 2022. Available from: https://www.istat.it/it/files/2022/09/Report-Ricerca-e-sviluppo-2020-2022.pdf. [Last accessed: 2024 October 23].
14. Larrue P, Guellec D, Sgard F. New trends in public research funding. In: Organisation for Economic Co-operation and Development (OECD), editor. OECD Science, Technology and Innovation Outlook Adapting to technological and societal disruption. Paris: OECD Publishing; 2018. doi: 10.1787/sti_in_outlook-2018-13-en.
15. Lepori B, Jongbloed BWA, Hicks D. Handbook of public funding of research. Cheltenham, UK; Northampton, MA, USA: Edward Elgar Publishing; 2023. PMID: 22919874.
16. Braun D. The role of funding agencies in the cognitive development of science. Res Policy. 1998 Dec;27(8):807-821. doi: 10.1016/S0048-7333(98)00092-4.
17. European Commission: Joint Research Centre, Lepori B. Analysis of National Public Research Funding (PREF) – Handbook for data collection and indicators production. Publications Office; 2017. doi: 10.2760/849945.
18. Glaser J, Serrano K. Changing funding arrangements and the production of scientific knowledge: introduction to the special issue. Minerva. 2018 Jan 29;56:1-10. doi: 10.1007/s11024-018-9344-6.
19. Italian National Institute of Statistics (ISTAT). Italian statistics yearbook [Annuario statistico italiano]: Istituto Nazionale di Statistica; 2022. Available from: https://www.aranagenzia.it/attachments/article/13572/ASI_2022.pdf. [Last accessed: 2024 October 23].
20. Piovani D, Nikolopoulos GK, Bonovas S. Non-communicable diseases: the invisible epidemic. J Clin Med. 2022 Oct 8;11(19):5939. doi: 10.3390/jcm11195939. PMID: 36233805; PMCID: PMC9572583.
21. World Health Organization (WHO). Global status report on noncommunicable diseases 2010. Geneva, Switzerland: World Health Organization; 2014.
22. Benziger CP, Roth GA, Moran AE. The Global Burden of Disease Study and the Preventable Burden of NCD. Glob Heart. 2016 Dec;11(4):393-397. doi: 10.1016/j.gheart.2016.10.024. PMID: 27938824.
23. The Lancet Global Health. Getting to the heart of non-communicable diseases. Lancet Glob Health. 2018 Sep;6(9):e933. doi: 10.1016/S2214-109X(18)30362-0. PMID: 30103982.
24. Ministero della Salute. Piano Nazionale della Cronicità. In: Dipartimento della Programmazione, dei Dispositivi Medici, del Farmaco e delle Politiche in favore del Servizio Sanitario Nazionale. Direzione Generale della Programmazione e dell’Edilizia Sanitaria, editors. 2024 ed. Roma; 2024.
25. Robinson JC. Funding of pharmaceutical innovation during and after the COVID-19 pandemic. JAMA. 2021 Mar 2;325(9):825-826. doi: 10.1001/jama.2020.25384. PMID: 33443546.
26. Vecchio R, Gentile L, Tafuri S, Costantino C, Odone A. Exploring future perspectives and pipeline progression in vaccine research and development. Ann Ig. 2024 Jul-Aug;36(4):446-461. doi: 10.7416/ai.2024.2614. Epub 2024 Mar 1. PMID: 38436081.
27. Filippini T, Zagnoli F, Bosi M, Giannone ME, Marchesi C, Vinceti M. An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy. Acta Biomed. 2021 Oct 1;92(S6):e2021420. doi: 10.23750/abm.v92iS6.12241. PMID: 34739462; PMCID: PMC8851028.
28. Florio M, Gamba S, Pancotti C. Mapping of long-term public and private investments in the development of Covid-19 vaccines. Eur Parliament COVI Committee. 2023: 1-95.
29. World Health Organization (WHO). An R&D blueprint for action to prevent epidemics. Plan of Action. Geneva: World Health Organization; 2016.
30. Millum J. Should health research funding be proportional to the burden of disease? Politics, Philosophy & Economics. 2023;22(1):76-99.
31. Cascini F, Gentili A. National Recovery and Resilience Plan and Health: qualitative analysis on the sustainability of the interventions on healthcare. Ann Ig. 2023 Sep-Oct;35(5):602-610. doi: 10.7416/ai.2023.2561. Epub 2023 Mar 3. PMID: 36866601.
32. Kalo Z, van den Akker LHM, Voko Z, Csanadi M, Pitter JG. Is there a fair allocation of healthcare research funds by the European Union? PLoS One. 2019 Apr 15;14(4):e0207046. doi: 10.1371/journal.pone.0207046. PMID: 30986207; PMCID: PMC6464186.
33. Filippini T, Vinceti SR. Italian National Recovery and Resilience Plan: a Healthcare Renaissance after the COVID-19 crisis? Acta Biomed. 2021 Nov 17;92(S6):e2021463. doi: 10.23750/abm.v92iS6.12339. PMID: 34787594; PMCID: PMC8851004.
34. Mayor S. Global alliance of funders of public health research agrees top priorities. BMJ. 2009 Nov 17;339:b4884. doi: 10.1136/bmj.b4884.
35. Ramani-Chander A, Thrift A, van Olmen J, Wouters E, Delobelle P, Vedanthan R, et al. Prioritising and planning scale-up research projects targeting non-communicable diseases: a mixed-method study by the Global Alliance for Chronic Diseases upscaling working group. BMJ Glob Health. 2023 Nov;8(11):e012804. doi: 10.1136/bmjgh-2023-012804. PMID:
37963611; PMCID: PMC10649516.
36. World Health Organization (WHO). Draft Fourteenth General Programme of Work (GPW14) (2025–2028). Draft Fourteenth General Programme of Work (GPW14) (2025–2028)2023.
37. Dalla Valle Z, Signorelli C, Renzi C. Primary care doctors retirements in the context of an ageing population in Italy. Ann Ig. 2024 Jul-Aug;36(4):392-404. doi: 10.7416/ai.2024.2602. PMID: 38299732.
38. Italian National Institute of Statistics (ISTAT). Populations and households; 2024. Available from: https://www.istat.it/en/population-and-households. [Last accessed: 2024 October 23].
39. European Environment Agency. Indicator AIR003 - Exceedance of air quality standards in Europe; Copenhagen, Denmark: European Environment Agency; 2024. Available from: https://www.eea.europa.eu//publications/europes-air-quality-status-2024. [Last accessed: 2024 October 23].
40. Filippini T, Rothman KJ, Goffi A, Ferrari F, Maffeis G, Orsini N, et al. Satellite-detected tropospheric nitrogen dioxide and spread of SARS-CoV-2 infection in Northern Italy. Sci Total Environ. 2020 Oct 15;739:140278. doi: 10.1016/j.scitotenv.2020.140278. Epub 2020 Jun 16. PMID: 32758963; PMCID: PMC7297152.
41. Palandri L, Rizzi C, Vandelli V, Filippini T, Ghinoi A, Carrozzi G, et al. Environmental, climatic, socio-economic factors and non-pharmacological interventions: A comprehensive four-domain risk assessment of COVID-19 hospitalization and death in Northern Italy. Int J Hyg Environ Health. 2024 Oct 3;263:114471. doi: 10.1016/j.ijheh.2024.114471. Epub 2024 Jun 6. PMID: 39366078.
42. Daou KN, Hakoum MB, Khamis AM, Bou-Karroum L, Ali A, Habib JR, et al. Public health journals’ requirements for authors to disclose funding and conflicts of interest: a cross-sectional study. BMC Public Health. 2018 Apr 23;18(1):533. doi: 10.1186/s12889-018-5456-z. PMID: 29688846; PMCID: PMC5913791.
43. Álvarez Bornstein B, Díaz-Faes A, Bordons M. What characterises funded biomedical research? Evidence from a basic and a clinical domain. Scientometrics. 2019 Mar 9;119:805-825. doi: 10.1007/s11192-019-03066-3.
44. Grassano N, Rotolo D, Hutton J, Lang F, Hopkins MM. Funding data from publication acknowledgments: coverage, uses, and limitations. JASIST. 2017;68(4):999-1017. doi: 10.1002/asi.23737.
45. Wang J, Shapira P. Funding acknowledgement analysis: an enhanced tool to investigate research sponsorship impacts: the case of nanotechnology. Scientometrics. 2011 Mar 5;87:563-586. doi: 10.1007/s11192-011-0362-5.
46. National Academies of Sciences Engineering, and Medicine; Policy and Global Affairs; Committee on Science, Engineering, Medicine, and Public Policy; Committee on Responsible Science. Fostering integrity in research. Washington (DC): National Academies Press (US); 2017 Apr 11. doi: 10.17226/21896. PMID: 29341557.
47. Di Federico S, Filippini T, Marchesi C, Vinceti M. Availability of open data related to COVID-19 epidemic in Italy. Ann Ig. 2023 May-Jun;35(3):344-358. doi: 10.7416/ai.2022.2514. Epub 2022 Sep 29. PMID: 36178129.
48. Sarli L, Monaco F. Does open data tell us everything? Acta Biomed. 2021 Dec 22;92(S2):e2021337. doi: 10.23750/abm.v92iS2.12715. PMID: 35037628.
49. Foundation Open Knowlege. The Open Definition; 2015. Available from: http://opendefinition.org/. [Last accessed: 2024 October 23].
50. Cocos M, Lepori B. What we know about research policy mix. Science and Public Policy. 2020 Apr 1;47:235-245. doi: 10.1093/scipol/scz061.
51. Schmutz A, Salignat C, Plotkina D, Devouassoux A, Lee T, Arnold M, et al. Mapping the global cancer research funding landscape. JNCI Cancer Spectr. 2019 Oct 7;3(4):pkz069. doi: 10.1093/jncics/pkz069. PMID: 32337488; PMCID: PMC7049992.
52. Lee M, Brandt N, Reyes CE, Mansour D, Maslow K, Sarkisian C. Practical Incorporation of Stakeholder-Informed Ethics into Research Funding Decisions. Prog Community Health Partnersh. 2024;18(3):389-396. doi:10.1353/cpr.2024.a937398. PMID: 39308383.
53. Pierson L. Accounting for future populations in health research. Bioethics. 2024 Jun;38(5):401-409. doi: 10.1111/bioe.13284. Epub 2024 Apr 11. PMID: 38602177.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Riccardo Mazzoli, Maria La Torre, Vanessa E. Privitera, Nadja Sändig, Tommaso Filippini, Marco Vinceti (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.